Last edition
News about "Infectious Disease Research"
Phase 2a study findings show RESP-X demonstrated safety, favourable dosing potential and encouraging efficacy signals, supporting further clinical development for respiratory patients colonised with Pseudomonas aeruginosa.
Infectious Disease Research | 25/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members